Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport dose-ranging for hip pain in CP
NCT00455637Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Mar 2007
- Primary completion
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of abobotulinumtoxinA in cerebral palsy (CP), sponsored by Ipsen. Started Mar 2007; status: terminated.
02
Drugs
abobotulinumtoxinA
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT00455637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455637.